Phase 1 11 trials
Phase 1
NCT07179770 Sep 2025 → Sep 2027 expected clear cell renal carcinoma NYU Langone Health
Recruiting
No outcome recorded
Phase 1
NCT07121959 Aug → Sep 2025 —
Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 1
NCT06903715 Mar → May 2025 —
Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 1
NCT06234605 Apr 2024 → Nov 2026 expected renal cell carcinoma HiberCell, Inc.
Recruiting
No outcome recorded
Phase 1
NCT04994522 Jul 2022 → Apr 2024 end stage renal failure , impaired renal function disease Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 1
NCT04995484 Jun 2022 → Dec 2023 —
Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 1
NCT05030506 Oct 2021 → Jun 2027 expected renal cell carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 1
NCT04846920 Jun 2021 → Apr 2026 clear cell renal carcinoma Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 1
NCT04627064 Dec 2020 → Feb 2024 clear cell renal carcinoma Dana-Farber Cancer Institute
Completed
No outcome recorded
Phase 1
NCT03445169 Feb → May 2018 —
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Completed
No outcome recorded
Phase 1
NCT02974738 Dec 2016 → Jan 2018 overdue adult glioblastoma , clear cell renal carcinoma Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Active not recruiting
No outcome recorded
Show 1 more trial Phase 1/2 5 trials
Phase 1/2
NCT07049926 Jul 2025 → Oct 2031 expected renal cell carcinoma Merck Sharp & Dohme LLC
Recruiting
No outcome recorded
Phase 1/2
NCT05468697 Aug 2022 → Jul 2026 overdue renal cell carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 1/2
NCT04626518 Dec 2020 → Jul 2026 overdue clear cell renal carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 1/2
NCT04626479 Dec 2020 → Jul 2026 overdue renal cell carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 1/2
NCT02861573 Nov 2016 → Oct 2027 expected castration-resistant prostate carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 2 14 trials
Phase 2
NCT07700758 Nov 2026 → Jan 2034 expected cancer Merck Sharp & Dohme LLC
Not yet recruiting
No outcome recorded
Phase 2
NCT07593040 Jun 2026 → Jan 2028 expected renal cell carcinoma Vall d'Hebron Institute of Oncology
Not yet recruiting
No outcome recorded
Phase 2
NCT07680205 Apr 2026 → Apr 2027 expected pheochromocytoma , pheochromocytoma-paraganglioma Cambridge University Hospitals NHS Foundation Trust
Recruiting
No outcome recorded
Phase 2
NCT07187778 Dec 2025 → Jul 2027 expected clear cell renal carcinoma M.D. Anderson Cancer Center
Recruiting
No outcome recorded
Phase 2
NCT07023432 Nov 2025 → Apr 2028 expected clear cell renal carcinoma M.D. Anderson Cancer Center
Recruiting
No outcome recorded
Phase 2
NCT06677190 Dec 2024 → Dec 2026 expected cervical cancer , endometrial cancer , ovarian carcinoma , vaginal cancer +1 Dana-Farber Cancer Institute
Recruiting
No outcome recorded
Phase 2
NCT06428396 Nov 2024 → May 2027 expected breast cancer Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 2
NCT05574712 Jan 2024 → Jan 2025 prostate cancer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Withdrawn
No outcome recorded
Phase 2
NCT07167329 Jan 2024 → Feb 2026 overdue clear cell renal carcinoma , endolymphatic sac tumor , hemangioblastoma , perifoveal exudative vascular anomalous complex +3 José Claudio Casali da Rocha
Recruiting
No outcome recorded
Phase 2
NCT04976634 Aug 2021 → Mar 2027 expected cancer Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 2
NCT04924075 Aug 2021 → Dec 2029 expected gastrointestinal stromal tumor , pancreatic neuroendocrine tumor , pheochromocytoma-paraganglioma , von Hippel-Lindau disease Merck Sharp & Dohme LLC
Recruiting
No outcome recorded
Phase 2
NCT04489771 Sep 2020 → Feb 2023 overdue renal cell carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 2
NCT03634540 Sep 2018 → Feb 2027 expected clear cell renal carcinoma Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Active not recruiting
No outcome recorded
Phase 2
NCT03401788 May 2018 → Apr 2027 expected hereditary clear cell renal cell carcinoma , von Hippel-Lindau disease Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Active not recruiting
No outcome recorded
Show 4 more trials Phase 3 8 trials
Phase 3
NCT07489495 Apr 2026 → Nov 2030 expected renal cell carcinoma Merck Sharp & Dohme LLC
Recruiting
No outcome recorded
Phase 3
NCT07405164 Mar 2026 → Jan 2034 expected cancer , von Hippel-Lindau disease Merck Sharp & Dohme LLC
Recruiting
No outcome recorded
Phase 3
NCT07227402 Nov 2025 → Feb 2032 expected renal cell carcinoma Merck Sharp & Dohme LLC
Recruiting
No outcome recorded
Phase 3
NCT05899049 Jul 2022 → Jun 2027 expected clear cell renal carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 3
NCT05239728 Mar 2022 → Oct 2026 expected renal cell carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 3
NCT04736706 Apr 2021 → Oct 2026 expected clear cell renal carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 3
NCT04586231 Feb 2021 → Feb 2026 overdue renal cell carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded
Phase 3
NCT04195750 Feb 2020 → Apr 2024 overdue renal cell carcinoma Merck Sharp & Dohme LLC
Active not recruiting
No outcome recorded